ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
Pfizer CDR CAD Hedged

Pfizer CDR CAD Hedged (PFE)

11,97
0,00
(0,00%)
Fermé 11 Février 10:00PM
Données en temps réel

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

Dernier
11,97
Prix Achat
11,90
Prix Vente
12,09
Volume échangé
-
0,00 Fourchette du Jour 0,00
0,00 Plage de 52 semaines 0,00
Clôture Veille
11,97
Ouverture
-
Dernière Transaction
Dernière heure de transaction
Volume moyen (3 m)
-
Volume financier
-
VWAP
-

PFE Dernières nouvelles

Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)

Enfortumab vedotin plus pembrolizumab continues to demonstrate superior efficacy versus chemotherapy in a broad population, reinforcing the combination as standard of care in first-line...

Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 Guidance

Full-Year 2024 Revenues of $63.6 Billion, Reflecting 7% Year-over-Year Operational Growth Excluding Contributions from Paxlovid and Comirnaty(1), Revenues Grew 12% Operationally Full-Year 2024...

Pfizer’s BRAFTOVI® Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 BREAKWATER Trial

BRAFTOVI in combination with cetuximab and mFOLFOX6 showed statistically significant and clinically meaningful improvement in progression-free survival and overall survival in patients with...

Pfizer to Showcase Advancements Across Genitourinary Cancers at ASCO GU Cancers Symposium

More than 20 abstracts span Pfizer’s leading genitourinary cancer portfolio of approved standards of care and growing pipeline across prostate and bladder cancers Detailed overall survival (OS...

Pfizer’s BRAFTOVI® Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer

Clinically meaningful and statistically significant results from the Phase 3 BREAKWATER trial show objective response rate of 61% with Pfizer’s BRAFTOVI combination regimen compared to 40% with...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

PFE - Frequently Asked Questions (FAQ)

What is the current Pfizer CDR CAD Hedged share price?
The current share price of Pfizer CDR CAD Hedged is $ 11,97
What is the 1 year trading range for Pfizer CDR CAD Hedged share price?
Pfizer CDR CAD Hedged has traded in the range of $ 0,00 to $ 0,00 during the past year

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
AEMXAGF Emerging Markets Ex China Fund
$ 28,74
(0,00%)
0
AEL.HAmseco Exploration Ltd
 0,00
(0,00%)
0
ADSLADSL Holdings Inc
 0,00
(0,00%)
0
ACCB.PAardvark 2 Capital Corp
 0,00
(0,00%)
0
ABXXAbaxx Technologies Inc
$ 10,52
(0,00%)
0
AEMXAGF Emerging Markets Ex China Fund
$ 28,74
(0,00%)
0
AEL.HAmseco Exploration Ltd
 0,00
(0,00%)
0
ADSLADSL Holdings Inc
 0,00
(0,00%)
0
ACCB.PAardvark 2 Capital Corp
 0,00
(0,00%)
0
ABXXAbaxx Technologies Inc
$ 10,52
(0,00%)
0
AEMXAGF Emerging Markets Ex China Fund
$ 28,74
(0,00%)
0
AEL.HAmseco Exploration Ltd
 0,00
(0,00%)
0
ADSLADSL Holdings Inc
 0,00
(0,00%)
0
ACCB.PAardvark 2 Capital Corp
 0,00
(0,00%)
0
ABXXAbaxx Technologies Inc
$ 10,52
(0,00%)
0
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock